The activity of cGMP-dependent protein kinase Iα is not directly regulated by oxidation-induced disulfide formation at cysteine 43

J Biol Chem. 2017 May 19;292(20):8262-8268. doi: 10.1074/jbc.C117.787358. Epub 2017 Mar 30.

Abstract

The type I cGMP-dependent protein kinases (PKGs) are key regulators of smooth muscle tone, cardiac hypertrophy, and other physiological processes. The two isoforms PKGIα and PKGIβ are thought to have unique functions because of their tissue-specific expression, different cGMP affinities, and isoform-specific protein-protein interactions. Recently, a non-canonical pathway of PKGIα activation has been proposed, in which PKGIα is activated in a cGMP-independent fashion via oxidation of Cys43, resulting in disulfide formation within the PKGIα N-terminal dimerization domain. A "redox-dead" knock-in mouse containing a C43S mutation exhibits phenotypes consistent with decreased PKGIα signaling, but the detailed mechanism of oxidation-induced PKGIα activation is unknown. Therefore, we examined oxidation-induced activation of PKGIα, and in contrast to previous findings, we observed that disulfide formation at Cys43 does not directly activate PKGIα in vitro or in intact cells. In transfected cells, phosphorylation of Ras homolog gene family member A (RhoA) and vasodilator-stimulated phosphoprotein was increased in response to 8-CPT-cGMP treatment, but not when disulfide formation in PKGIα was induced by H2O2 Using purified enzymes, we found that the Cys43 oxidation had no effect on basal kinase activity or Km and Vmax values; however, PKGIα containing the C43S mutation was less responsive to cGMP-induced activation. This reduction in cGMP affinity may in part explain the PKGIα loss-of-function phenotype of the C43S knock-in mouse. In conclusion, disulfide formation at Cys43 does not directly activate PKGIα, and the C43S-mutant PKGIα has a higher Ka for cGMP. Our results highlight that mutant enzymes should be carefully biochemically characterized before making in vivo inferences.

Keywords: Rho (Rho GTPase); VASP; allosteric regulation; cGMP-dependent protein kinase; cyclic GMP (cGMP); enzyme kinetics; oxidation-reduction (redox).

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Amino Acid Substitution
  • Animals
  • Cell Line
  • Cyclic GMP / analogs & derivatives
  • Cyclic GMP / pharmacology
  • Cyclic GMP-Dependent Protein Kinase Type I / genetics
  • Cyclic GMP-Dependent Protein Kinase Type I / metabolism*
  • Disulfides / metabolism*
  • Enzyme Activation / drug effects
  • Enzyme Activation / physiology
  • Gene Knock-In Techniques
  • Humans
  • Mice
  • Mice, Transgenic
  • Mutation, Missense
  • Oxidation-Reduction
  • Protein Multimerization / drug effects
  • Protein Multimerization / physiology*
  • Thionucleotides / pharmacology

Substances

  • Disulfides
  • Thionucleotides
  • 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP
  • Cyclic GMP-Dependent Protein Kinase Type I
  • Cyclic GMP